

Anti-Infectives: Market Research Report

<https://marketpublishers.com/r/A8F8999013DEN.html>

Date: February 2010

Pages: 825

Price: US\$ 3,950.00 (Single User License)

ID: A8F8999013DEN

Abstracts

This report analyzes the worldwide markets for Anti-Infectives in US\$ Million.

The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World.

Annual forecasts are provided for each region for the period 2006 through 2015.

The report profiles 77 companies including many key and niche players worldwide such as Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma, Inc., AstraZeneca PLC , Bayer HealthCare AG , Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, . F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-Aventis SA, and Wyeth Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW & DYNAMICS

Introduction
Anti-Infective Drugs – Mechanism of Action
Increasing Drug Resistance – A Major Challenge to Reckon With
Antibacterial Resistance Costs High
Novel Approaches to Combat Drug-Resistant Strains
Combination Therapy
New Approach to Directly Target Illness Rather than Infection
Antivirals Directed at Human Targets
Immunomodulation
Antivirulence
Select Companies Involved in Anti-Virulence Drug Research
Pipeline Analysis of Anti-Infectives by Therapeutic Class

Table 1. Anti-Infectives Pipeline by Therapeutic Class and Development Stage:(includes corresponding Graph/Chart)

Injectables Gain Traction
Market Outlook
Anti-Bacterials Drive Global Anti-Infectives Market

Table 2. World Market for Anti-Infectives (2008): Percentage Share Breakdown of Value Sales by Therapeutic Class – Anti-Bacterials, Anti-Virals, Anti-Fungals, and Others (includes corresponding Graph/Chart)

Anti-Virals – A Significant Market
Original Brands Leads the Supreme

Table 3. Global Market for Anti-Infectives by Licensing Status (2006-07): Percentage Share Breakdown of Value Sales for Branded, Licensed Brands, Unbranded Drugs, and Other Drugs (includes corresponding Graph/Chart)

United States - The Largest Anti-infectives Market Globally

Table 4. World Market for Anti-Infectives by Geographic Region (2010): Percentage Share Breakdown for US, Japan, Europe, and Rest of World (includes corresponding Graph/Chart)

Table 5. World Market for Anti-Infectives: Breakdown of Select Geographic Regions/Country by Value Growth Potential for the Period 2006-2015 (includes corresponding Graph/Chart)

Europe – The Second Leading Worldwide Market for Anti-Infectives
Competitive Landscape

Table 6. Worldwide Anti-Infectives Market by Leading Players (2007): Percentage Share Breakdown of Value Sales for Glaxo SmithKline, Merck, Pfizer, Novartis, Gilead Sciences, Abbott, Wyeth, Sanofi-Aventis, Bristol-Myers Squibb, Johnson & Johnson (includes corresponding Graph/Chart)

Table 7. Leading Anti-Infective Companies Worldwide and their Brands: Value Sales for the year 2008 (includes corresponding Graph/Chart)

GlaxoSmithKline Portfolio of Anti-Infectives – Breakdown by Therapeutic Class

2.ANTI-BACTERIALS MARKET

Market Estimates and Forecasts
Market Analysis by Drug Class

Table 8. Worldwide Market for Anti-Bacterials by Major Drug Class (2008): Percentage Share Breakdown for Cephalosporins, Macrolides, Fluoroquinolones, Penicillins, and Others (includes corresponding Graph/Chart)

Market Analysis by Region
Competition in Anti-Bacterials Market

Table 9. World Anti-Bacterials Market (2008): Break-Up of Value Sales (US\$ Billion) for Leading Drugs (includes corresponding Graph/Chart)

Global Market Outlook

Antibacterial Resistance – A Key Growth Dampener

Antibiotic-Resistant Bacteria by Type

Bacterial Resistance to Most Commonly Used Antibacterial Drug Class: Incidence Level in Select Countries

Generic Competition Intensifies

Patent Expiries Commoditize Antibiotics

Patent Expiries of Major Anti-Bacterial Drugs

R&D Initiatives Imperative for Developing Novel Drugs to Combat Drug-Resistant Strains

Hospital Market for Gram-Positive Antibacterials to Witness Encouraging Gains

Anti-MRSA Antibiotics Find Their Way

What are Anti-bacterials?

Taxonomy of Anti-bacterials

Classification of Anti-bacterials based on Mechanism of Action

Antibacterial Drug Classes

Penicillin

Cephalosporins

Side Effects

Fluroquinolones

Side Effects

Tetracyclines

Treatment

Side Effects

Macrolides

Treatment

Side Effects

Others

Classification based on the Process of Suppressing or Killing Bacteria
Bactericidal or Bacteria Destroying Drugs
Bacteriostatic Drugs
Bacterial Spectrum
Use of Antibacterial Drugs: An Overview
Phage Therapy, a Promising Approach for Bacterial Infections
How Does Phage Therapy Works?
Treatment and Application of Phase Therapy
Phages for Antibiotic-Resistant Bacteria
Companies Involved in Phage Therapy Research

3.ANTI-VIRALS MARKET

Market Estimates and Forecasts
Five Major Anti-Virals Dominate the Antivirals Market
Players Active in Anti-Virals Market

Table 10. Major Anti-Viral Drugs of GSK and Bristol-Myers Squibb: Annual Sales for the year 2008 (includes corresponding Graph/Chart)

Market Leaders In 2008: A Review

Table 11. World Anti-Virals Market (2008): Break-Up of Value Sales (US\$ Billion) For Leading Drugs (includes corresponding Graph/Chart)

Key Trends and Issues
Preventative Antivirals Gain Significance

Table 12. Global Market for Anti-Virals (2007): Percentage Share Breakdown by Category – Antiviral Therapeutics, Vaccines, Monoclonal Antibodies, and Others (includes corresponding Graph/Chart)

R&D Initiatives Abound in Antivirals Market
Companies Involved in Late-Stage Development of Anti-virals
Companies Involved in Phase II Clinical Studies of Anti-virals
Companies Involved in Phase I Clinical Studies of Anti-virals

Select Companies in Pre-clinical Development Phase of Anti-virals
Development of Direct Targeted Antiviral Therapies
New Novel Anti-Viral Peptides
siRNA Shows Antiviral Potential
Combination Drug Therapy Gains Popularity
Microbiocides, a New Way to Fight STD and HIV Infections
What are Anti-Virals?
Emergence of Antivirals
Types of Antivirals
Entry Blockers
Drugs in the Market
Viral Component Replication Blockers
Viral Component Assimilation Blockers
Antisense Molecules
Synthetic Ribozymes
Protease Inhibitors
Blockers for Release of Completed Viruses from the Host Cell
Other Types of Antivirals
Interferons
Synthetic Monoclonal Antibodies
Major Viral Infections & Related Drugs
Human Immunodeficiency Virus (HIV)
HIV Treatment – The Largest in Anti-Virals Sector
Major Anti-HIV/AIDS Drugs by Category
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Major Nucleoside Reverse Transcriptase Inhibitors (NRTIs):
Epivir (Lamivudine)
Retrovir (Zidovudine)*
Combivir (Epivir+Retrovir)
Videx (Didanosine)
Zerit (Stavudine)
Hivid (Zalcitabine)
Protease Inhibitors (PIs)
Major Protease Inhibitors:
Norvir (Ritonavir)
Kaletra (Lopinavir+Ritonavir)
Invirase (Saquinavir)
Fosamprenavir
Integrase Inhibitors (IIs)

ISENTRESS**Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)****Entry Blockers****Fusion Inhibitors****Fuzeon (Enfuvirtide)****Antiviral siRNAs****Drugs for HIV Infected Patients in Advanced Stage****Combination Therapies For HIV Infected Patients****Hepatitis Infection****Acute and Chronic Hepatitis Infections****Treatment Regimen for Hepatitis Infection****Interferons****Standard Interferons****Pegylated Interferons****Ribavirin****Types of Hepatitis Infection based on Strains****Hepatitis A Virus (HAV) Infection****Hepatitis B Virus (HBV) Infection****Treatment for Chronic HBV Infection****Vaccines Dominate the Category****Antiviral Drugs for Chronic HBV Infection****Major Anti-HBV Drugs:****Hepatitis C Virus (HCV) Infection****Treatment for Chronic Hepatitis C Infection****Some Alternative Treatments****Drugs in Pipeline:****Hepatitis C - Drugs in Pipeline As on March 2008****Hepatitis D Virus (HDV) Infection****Hepatitis E Virus (HEV) Infection****Herpes Simplex Virus (HSV) Infection****Treatment for HSV Infection****Major HSV Drugs Worldwide and their Patent Expiries****Antivirals for HSV Infection****Select HSV Infection Drugs****Zovirax (Aciclovir)****Famvir (Famciclovir)****Foscavir (Foscarnet)****Valtrex (Valaciclovir)****Vectavir/Denavir (Penciclovir)**

Abreva (Docosanol)
Ophthalmic Viral Infections & Related Drugs
Cytovene (Ganciclovir)
Vistide (Cidofovir)
Foscavir (Foscarnet)
Human Papilloma Virus (HPV)
Treatment for HPV Infection
Respiratory Viruses Infections
Influenza Virus
Treatment for Influenza
Major Influenza Drugs Profile
Symmetrel® (Amantadine)
Flumadine (Rimantadine)
Tamiflu (Oseltamivir)
Relenza (Zanamivir)
Respiratory Syncytial Virus (RSV) Infection
Treatment for RSV and other Respiratory Viral Infections
Other Types of Viral Diseases
Treatment for Other Viral Diseases

4.ANTI-FUNGALS MARKET

Anti-Fungals Market – A Quick Review
Current and Future Analysis
Anti-fungals: An Introduction
Classification of Anti-Fungal Drugs by Class
Allylamines
Select Systemic and Topical Anti-Fungal Drugs Classified under Allylamines Group
Azoles
Select Systemic and Topical Anti-Fungal Drugs Classified under Azoles Group
Polyene Macrolides
Select Systemic and Topical Anti-Fungal Drugs Classified under Polyene Macrolides Group
Others
Other Systemic and Topical Anti-Fungal Drugs
Fungal Infections & Treatment
Aspergillosis – Disease & Symptoms
General Syndromes of Aspergillosis & Treatment Options
Pulmonary Aspergillosis

Aspergilloma
Invasive Aspergillosis
Select Drugs Used for the Treatment of Invasive Aspergillosis
Blastomycosis – Disease & Symptoms
Blastomycosis Treatment: Azoles the Preferred Choice
Select Drugs or Medications Used For Blastomycosis Fungal Infection Treatment
Candidiasis – Disease & Symptoms
General Syndromes of Candidiasis & Treatment Options
Mucocutaneous Candidiasis
Treatment Options
Select Drugs or Medications Used for the Treatment of Cutaneous Candidiasis
Invasive Candidiasis
Treatment Options
Cryptococcosis & Clinical Syndromes
Treatment of Cryptococcosis
Select Drugs Used for the Treatment of Cryptococcosis
Histoplasmosis – Disease and Symptoms
Treatment Options for Histoplasmosis
Select Drugs Used for the Treatment of Histoplasmosis

5. AN OVERVIEW OF VACCINES MARKET

Introduction
Serum Institute of India Ltd. – A Major Player in Vaccines Market
Other Major Players Active in Vaccines Market

Table 13. Vaccines Portfolio of GlaxoSmithKline and Merck: Breakdown of Annual Sales (in US\$ Million) for the year 2008 (includes corresponding Graph/Chart)

Select Infectious Diseases and Vaccines
Infectious Diseases
Diphtheria
Tetanus (Lockjaw)
Pertussis (Whooping Cough)
Vaccines for Diphtheria, Tetanus and Pertussis
Select Diphtheria Vaccines by Company
DTaP – A Combination Vaccine for Diphtheria, Tetanus and Pertussis
DT - A Combination Vaccine for Diphtheria and Tetanus

Td - The Tetanus and Diphtheria Vaccine
Tdap – A Vaccine for Tetanus, Diphtheria and Pertussis
Measles
Live, Attenuated (Freeze-Dried) Measles Vaccine
Mumps
MMR – A Combination Vaccine for Measles, Mumps and Rubella
Side Effects of MMR Vaccine
Polio & Vaccines
Influenza Vaccines
Hepatitis B Vaccine
HPV Infection Vaccines
HIV Vaccines – Research Clipped by Lack of Funds

6.RESEARCH & DEVELOPMENT

Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax Treatment
Novartis Initiates Phase IIb Clinical Trials of Albuferon®
Schering-Plough Concludes Phase III Trials for INTRON A® Plus REBETOL™
Combination Therapy
Progenics Advances Research on New Antibody Therapy for HIV
Forest Labs Announces Encouraging Phase III Results of Ceftaroline
Pharmasset Completes Phase 1a Trial of PSI-7851, Initiates Phase 1b Study
Roche Announces Positive Results of PEGASYS/ COPEGUS Combination Therapy
Novartis Announces Phase III Results of Menveo® Vaccine
Discovery Laboratories Announces Pre-Clinical Results of SURFAXIN®
Emergent Commences Phase II Clinical Study of Typhoid Vaccine
Enanta Begins Phase I Trial of EDP-322, the First MRSA-Active Bicyclolide
Roche, Pharmasset, InterMune Being Oral Anti-Virals Dual-Combination Study
ANRS, Pharmasset, Gilead Initiate Clevudine + Viread® Clinical Trials

7.PRODUCT LAUNCHES

Rx Africa (Ethiopia) to Introduce Generic Pharmaceuticals
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug
Galderma Laboratories Launches Epiduo™ Gel
Ranbaxy Rolls Out Generic Valtrex
Glenmark Introduces Onabet Topical Antifungal Cream
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin
Watson Pharma Introduces Biaxin XL's Generic Version

Taisho Toyama Pharmaceutical Rolls Out Zosyn®
GSK Launches ALTARGO® in the UK
Toyama Launches New Garenoxacin Quinolone Antibiotic
Wockhardt to Introduce Cefprozil in the US
MSD India Launches Invanza in India
Macrolide Antibiotic Developed in the US
University of Michigan Devises NMR Spectroscopy for Antibiotics
Glycopeptide-Cephalosporin Antibiotics Developed in the US

8.RECENT INDUSTRY ACTIVITY

Merck Merges with Schering-Plough
Beactica and Cubist Sign Agreement
Akela Pharma Acquires Nventa Biopharmaceuticals
GSK and Pfizer Establish New JV for Developing Anti-HIV Drugs
Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery
Grindeks Commences Production of Anti-flu Drug, Rimantadine-Grindeks
Galapagos Expands Partnership with GSK
GSK Acquires Stiefel
The Medicines Company Acquires Targanta
Tibotec Signs Licensing and Partnership Deal with Gilead
Abbott Buys Ibis Biosciences
Elder and Strides on Expansion Mode
Kemin Industries Acquires Amalyte Pharmaceuticals
Valeant Pharmaceuticals International Acquires EMO-FARM
Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma
moksha8 Extends Partnership with Roche
Akorn Signs Agreement with Eli Lilly and Company
Access Pharmaceuticals Acquires MacroChem
Vertex Pharmaceuticals Acquires ViroChem Pharma
sanofi-aventis Acquires Laboratorios Kendrick
DSM Enters into Joint Venture with North China Pharmaceutical Group
NovaBay Inks Agreement with Medical University of Innsbruck
Tibotec Collaborates with Global Alliance for TB Drug Development
DSM Aired Plans to Divest DSM Deretil
3I TO BUY ALPHARMA UNIT
Three Rivers Acquires Infergen® HCV Drug From Valeant
ULL Establishes New Antibiotics Unit in Himachal Pradesh
Biocat to Expand Presence in the Indian Market

Ranbaxy Signs Agreement with Merck
Zydus Acquires Controlling Interest in Simayla Pharmaceuticals
Novartis to Acquire Protez
Marksans Acquires Relonchem
Orchid Signs Licensing Agreement with Merck
Forest and Novexel Sign Licensing Agreement
Sanofi-aventis Collaborates with Novozymes
Janssen-Cilag International Obtains Marketing Authorization for INTELENCETM
Nastech Pharmaceutical Company Changes Name to MDRNA
Galderma Laboratories Acquires CollaGenex Pharmaceuticals
Emergent BioSolutions Forges Joint Venture with the University of Oxford
Emergent BioSolutions to Acquire Recombinant Flu Vaccine, FluBlok®
AstraZeneca Acquires Arrow Therapeutics
Cubist Submits INDs for CB-182,804 and CB-183,315
SRI International Partners with Blanca Pharmaceuticals to Develop Antibiotics
Allergan Acquires Esprit Pharma
GSK And Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals
J&J PRD Seeks FDA Approval for Doripenem Antibiotic
J&JPRD Seeks FDA Approval for Ceftobiprole
GSK to Cease Sale of Amprenavir Protease Inhibitor
Iroko Bags Canadian Rights to Vancocin®
AstraZeneca Purchases Biologics Production Facility from DSM Biologics
Depomed Expands Agreement with Watson Pharmaceuticals
Depomed Terminates Agreement with Esprit Pharma
Phylogica and Dynamic Microbials Inks Agreement
Pharmasset Collaborates with University of Cincinnati
Homeland Safety International Acquires Majority Stake in PLC Marketing
Ecopia and Caprion Merge to Form Thallion Pharmaceuticals

9.DRUG APPROVALS

FDA Clears Extended Therapy with INTRON A in Chronic HCV Patients
Abbott Obtains EC Approval for Kaletra® in Treating HIV Patients
Tibotec Gets EC Clearance for PREZISTA® in Treating HIV Patients
Health Canada Approves Anti-HIV?1 Drug, ISENTRESS®
Mylan Receives FDA Approval for Linezolid 600 mg Tablets
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden
MiddleBrook Obtains NDA Approval for MOXATAG™
Tibotec Pharmaceuticals Obtains US FDA Approval for PREZISTA®

Wyeth Receives an Approvable Letter from US FDA for TYGACIL®
Astellas Pharma Receives Approval from US FDA for MYCAMINE®
Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN®
Cubist Receives EC Approval for Extended Use of Cubicin®
GSK Receives Approval for ALTARGO® in Europe
Cubist Gains Approval for CUBICIN in Taiwan and South Korea

10.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Alcon Pharmaceuticals Ltd. (Switzerland)
Astellas Pharma, Inc. (Japan)
AstraZeneca PLC (UK)
Bayer HealthCare AG (Germany)
Bristol-Myers Squibb Co. (USA)
Boehringer Ingelheim (Germany)
Cubist Pharmaceuticals, Inc. (USA)
Daiichi Sankyo Company, Limited (Japan)
Eli Lilly and Company (USA)
Gilead Sciences, Inc. (USA)
GlaxoSmithKline Plc (UK)
F. Hoffmann-La Roche, Ltd. (Switzerland)
Johnson & Johnson (USA)
Merck & Co., Inc (USA)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Sanofi-Aventis SA (France)

Table 14. The below table exhibits worldwide vaccines sales of the company for the year 2008: (includes corresponding Graph/Chart)

Wyeth Pharmaceuticals, Inc. (USA)

11.GLOBAL MARKET PERSPECTIVE

Anti-infectives by Region:

Table 15. World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 16. World 10-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Dollar Revenues for the US, Japan, Europe, and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)

Anti-Infectives by Therapeutic Class:

Table 17. World Recent Past, Current & Future Analysis for Anti-Infectives by Therapeutic Class – Antibacterials, Antivirals, Antifungals, and Others* Markets Independently Analyzed by Annual Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 18. World 10-Year Perspective for Anti-Infectives by Therapeutic Class - Percentage Breakdown of Dollar Revenues for Antibacterials, Antivirals, Antifungals, and Others* Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)

Anti-bacterials by Region:

Table 19. World Recent Past, Current & Future Analysis for Anti-Bacterials by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 20. World 10-Year Perspective for Anti-Bacterials by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

Anti-bacterials By Drug-Class:

Table 21. World Recent Past, Current & Future Analysis for Anti-Bacterials by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006

through 2015 (includes corresponding Graph/Chart)

Table 22. World 10-Year Perspective for Anti-Bacterials by Drug Class - Percentage Breakdown of Annual Sales Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart)

Table 23. World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 24. World 10-Year Perspective for Cephalosporins by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

Table 25. World Recent Past, Current & Future Analysis for Penicillins by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 26. World 10-Year Perspective for Penicillins by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

Table 27. World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 28. World 10-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

Table 29. World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 30. World 10-Year Perspective for Macrolides by Geographic Region- Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

Table 31. World Recent Past, Current & Future Analysis for Other Anti-bacterials by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US\$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 32. World 10-Year Perspective for Other Anti-bacterials by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

HIV Market Perspective in the US

HIV/AIDS - Prevalence

Homosexual Males – A Significant Risk Group for HIV Infections

Women – A High Risk Group for HIV/AIDS

African-Americans - The Leading High Risk Ethnic Group for HIV Infection

Latinos - The Second Major Ethnic Risk Group for HIV Infection

An Overview of Sexually Transmitted Diseases (STDs)

Regulatory Environment

Product Innovations/Introductions

Strategic Corporate Developments

FDA Regulations And Approvals

Focus on Select Players

B. MARKET ANALYTICS

Table 33. US Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 34. US Recent Past, Current & Future Analysis for Anti-Bacterials Market by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Analyzed by Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 35. US 10-year Perspective for Anti-Bacterials Market by Drug Class – Percentage Breakdown of Dollars Sales Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

2.JAPAN

A. MARKET ANALYSIS

Infectious Disease Market Witnessing Mixed Fortunes in Japan

HIV Infection Prevalence – One of the Lowest Worldwide

Hepatitis C Prevalence – Widespread and Driving the Hepatitis C Drugs Market

Table 36. Leading Hepatitis C Anti-viral Products in Japan (2008(E)): Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron, and Others (includes corresponding Graph/Chart)

Product Innovations/Introductions

Focus on Select Players

B. MARKET ANALYTICS

Table 37. Japanese Recent Past, Current & Future Analysis for Anti-Infectives Market – Annual Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3.EUROPE

A. MARKET ANALYSIS

Strategic Corporate Developments

B. MARKET ANALYTICS

Table 38. European Recent Past, Current & Future Analysis for Anti-Infectives Market by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Analyzed by Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 39. European 10-year Perspective for Anti-Infectives Market by Geographic Region – Percentage Breakdown of Dollars Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

3A.FRANCE

A. MARKET ANALYSIS

France - The Largest Market for Anti-Infectives in Europe
Antibiotics Use Takes A Dip, As Regulatory Authorities' Efforts Pays Off
Strategic Corporate Development
Focus on Select Players
Sanofi-Aventis SA

Table 40. The below table exhibits worldwide vaccines sales of the company for the year 2008: (includes corresponding Graph/Chart)

B. MARKET ANALYTICS

Table 41. French Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3B.GERMANY

A. MARKET ANALYSIS

Strategic Corporate Development
Focus on Select Players

B. MARKET ANALYTICS

Table 42. German Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3C.ITALY

Market Analysis

Table 43. Italian Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3D.THE UNITED KINGDOM

A. MARKET ANALYSIS

Infectious Diseases – A Quick Primer

Table 44. Number of new Cases, and Deaths due to Infectious Disorders in England (2006): Breakdown by Infection Type (includes corresponding Graph/Chart)

Research and Development of New Anti-Infectives

Table 45. Number of New Anti-Infectives Approved in UK (2003-2007): Breakdown by Therapeutic Class – Anti-Virals and Anti-Bacterials

Impediments to the Development of New Anti-infectives

Scientific Barriers

Economic Barriers

Regulatory Barriers

HIV/AIDS Prevalence – On the Rise
Drug Resistant HIV Strains - Incidence Rising
STD – Rising Incidence Poses Health Risks
Product Innovations/Introductions
Strategic Corporate Developments
Focus on Select Players

B. MARKET ANALYTICS

Table 46. UK Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3E.SPAIN

Market Analysis

Table 47. Spanish Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3F.REST OF EUROPE

A. MARKET ANALYSIS

Focus on Select Market
Russia – Leading the Prevalence of HIV/AIDS
Acute Drug Supply Shortages Risk Lives HIV Victims
Strategic Corporate Developments
Focus on Select Players

B. MARKET ANALYTICS

Table 48. Rest of Europe Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Focus on Select Markets

Canada

HIV/AIDS Prevalence

Asia-Pacific

HIV/AIDS Prevalence

HIV Infection Rising Among Male

Australia

HIV/AIDS Prevalence

Chronic Hepatitis C Prevalence

Bangladesh

HIV/AIDS Prevalence

Cambodia

HIV/AIDS Prevalence

China

HIV/AIDS Prevalence

Antibiotics Market

Antibiotics Manufacturing

Carbapenem Antibiotics Hold Great Potential

China Represents a Major Market for Hepatitis B Therapies

India

HIV/AIDS Prevalence

Not-for-Profit Organizations Active in HIV/AIDS Control and Prevention

AIDS Control Programs for Rural Youths in India

Anti-Infectives Market Experiencing Double- Digit Growth

Table 49. Pharmaceutical Market in India (2007): Percentage Market Share Breakdown by Therapeutic Class (includes corresponding Graph/Chart)

Competition

Top 5 Drug Producers in India, and their Major Products

Injectable Antibiotics Demonstrate Robust Growth

New Initiative to Develop Novel Antibiotic Molecules

Major Players - Hepatitis B Vaccines

Product Innovations/Introductions

Strategic Corporate Developments
Focus on Select Players

B. MARKET ANALYTICS

Table 50. Rest of World Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 51. Rest of World Recent Past, Current & Future Analysis for Anti-Bacterials Market by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Analyzed by Annual Sales Revenues in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 52. Rest of World 10-year Perspective for Anti-Bacterials Market by Drug Class – Percentage Breakdown of Dollars Sales Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 77 (including Divisions/Subsidiaries - 85)

Region/Country/Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

I would like to order

Product name: Anti-Infectives: Market Research Report

Product link: <https://marketpublishers.com/r/A8F8999013DEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A8F8999013DEN.html>